MemantineMarket, by Formulation (Tablet and Capsule), by Distribution Channel(Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and byGeography (North America, Europe, Asia Pacific, Latin America, Middle East, andAfrica) -Size, Share, Outlook, and Opportunity Analysis 2018 – 2026
Memantine is a non-acetylcholinesterase inhibitor drug that aids in treatment of Alzheimer's disease.The drug received European marketing approval in 2002 and the U.S. Food andDrug Administration (U.S FDA) approval in 2003. The generic versions of thedrugs are available since 2015. Memantine aids in treatment of moderate tosevere dementia associated with Alzheimer's disease. However the drug may showa severe skin reaction called Stevens-Johnson syndrome (associated with painfulblisters on the skin) after prolonged use.
Memantine Market– Drivers
Increasing number of pipelinestudies for use of memantine are expected to boost growth of the memantinemarket. For instance, in September 2016, Lille University Hospital startedphase I clinical study for assessing the effects of memantine on cognitivebehavior of patients associated with Alzheimer’s disease. The study is estimatedto be completed by February 2019.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2255
Furthermore, Suven Life SciencesLimited is undergoing phase II clinical study for the comparative study onsafety and efficacy of SUVN-502 along with memantine HCl and donezepil HCl fortreating moderate Alzheimer’s disease. The study was started in September 2015and is expected to be completed in May 2019.
Memantine Market– Restraint
Increasing number of expiredpatents of drugs is a major factor hindering growth of the global memantinemarket. For instance, according Merz Pharmaceuticals, a Germany-based company,in October 2018, overall licensing income during patented period for memantinedecreased due to expiration of patent protection in a majority of markets. Forinstance, according to Merz Pharmaceuticals, the U.S. licensing income formemantine declined to US$ 138.07 million in 2017-18 compared to US$ 183.34million in year 2016.
Memantine Market– RegionalAnalysis
On the basis of region, theglobal memantine market is segmented into North America, Latin America, Europe,Asia Pacific, Middle East, and Africa.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/memantine-market-2255
North America is expected to holddominant position in the global memantine market, owing to increasing number ofgeneric versions of memantine in the U.S. market. For instance, in February2018, Lupin Limited announced the launch of its Memantine HydrochlorideExtended-Release Capsules in the U.S. market. The capsules are available in7mg, 14mg, 21mg, and 28mg, for which company has received an approval from theU.S. FDA. These are indicated for the treatment of moderate to severe dementiaof the Alzheimer’s disease.
Furthermore, Asia Pacific isexpected to witness significant growth in the global memantine market, owing toincreasing focus of key players in manufacturing memantine tablets. Forinstance, in October 2018, Dr. Reddy’s Laboratories launched memantinehydrochloride tablets in the Indian market. They are available in 5mg and 10mg,equivalent to generic version of Namenda tablets, which were already availablein the U.S. market in July 2015.
Memantine Market– CompetitiveAnalysis
Key players operating in theglobal memantine market include, Merz Pharmaceuticals, Lupin Limited, Allerganplc. Novartis AG, Daiichi Sankyo Company, Limited, Ono Pharmaceutical Co Ltd.,Eisai Co., Ltd., H. Lundbeck A/S, Dr. Reddy’s Laboratories, and Johnson &Johnson Services, Inc.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2255
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
